Objective Comparative study of MRI gadolinium contrast agent enhancement efficacy: gadoterate meglumine(cyclic chelate), gadopentetate(chain chelate), gadodiamide(chain chelate), gadopentetate dimeglumine (chain chelate) in breast fibroadenoma. Methods Collected 120 cases MRI datas of breast fibroadenoma confirmed by pathology, were randomly divided into 4 groups, each group of 30 cases, gadolinium contrast agent were used gadoterate meglumine, gadopentetate, gadodiamide or gadopentetate dimeglumine. MRI dynamic enhancement using fast small angle excitation three-dimensional imaging lipid-suppressing T1WI sequence. The MRI signal strength values of each case were recorded and the maximum contrast enhancement rate (MCER) was calculated. SI values were compared using single factor analysis of variance, MRCE comparison using Kruskal-Walls test. The adverse effects of contrast agents were recorded. Results The group of used gadoterate meglumine, TIC curve includes 26 cases of inflow type and 4 cases of ascending platform type. The group of used gadopentetate, the types of TIC curves were 24 cases of inflow type and 6 cases of ascending platform type. The group of used gadoterate meglumine, TIC curve includes 28 cases of inflow type and 2 cases of ascending platform type. The group of used gadopentetate , the types of TIC curves were 28 cases of inflow type and 2 cases of ascending platform type. After statistical analysis, the difference in each group of the length and short diameter of tumor, the initial SI value, the end SI value, the MRCE, the SNR and CNR were not statistically significant. No adverse reactions occurred in 120 patients. Conclusion The molecular type of gadoterate meglumine is cyclic, and the molecular type of gadopentetate, gadodiamide, and gadopentetate dimeglumine is linear. Based on the molecular structure, gadoterate meglumine is superior to the other three kinds of gadolinium contrast agents. In this study, there was no significant difference in enhancement performance between those four kinds gadolinium contrast agents, and no adverse reactions occurred.